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8 Oral PresentationsTable 1. Cumulative incidence of AGVHD, NRM and Relapse
according to HLA typing and kind of conditioning
RIC Std11HLA siblings
AGVHD (D100) Gr I 15% [9-20,5] 34% [19-49]
Gr II 15% [9-21,4] 9,5% [7-49]
Gr III-IV 11% [6-16] 12% [2-22]
NRM at 1 year 8,4% [12-25] 23% [11-35.6]
Relapse at 1 year 13% [8 -19] 6% [0-14]Unrelated Donors
AGVHD (D100) Gr I 13% [6-20] 22% [4-39]
Gr II 22% [13-30] 26% [7,5-45]
Gr III-IV 14% [7-21] 22% [4-39]
NRM at 1 year 24% [16-32] 36% [17-55]
Relapse at 1 year 16% [9-23] 4% [0-12]The CI of lim. and ext. cGVHD at 1 yr, were 15 % (6–24) and
29.5% (18–41) for Std; 18.6 (13–24) and 18% (13–23) for RIC re-
spectively. With a median follow up of 38 months, the 3 and 5-yr
OS and DFS were 56% (51–62) and 47.4 % (42–53); 49 % (43–56)
and 42% (36–48.5) respectively. We observed a significant difference
concerning 5-yr OS according to the pretransplant disease status
[CR: 73% (60–89), PR: 57% (48–68) and PD: 35% (26–46)]
(p\0.00001).There was no significant difference between std and
RIC in term of OS with 52.4 % (42–66) and 47% (40–55.5) respec-
tively (p 5 0.44) [Std and RIC Sib: 51% (37–70) and 56% (47–67);
Std and RIC UD: 60% (44–83) and 40% (29–55) respectively].
The multivariate analysis showed a significant impact of 3 factors
on OS: age: HR 5 1.061 (1.02–1.10) p\0.0001, gender: HR 5
2.29 (1.02–5.11) p 5 0.04 and PS: HR 5 3.15 (1.40–7.10) p 5
0.005.The CI of non-relapse and relapse mortality (NRM and
RM) at 3 months and 1 yr were: 10 % (7–13), 5% (3–7) and 24%
(19–28), 15% (12–19) respectively [Std:23 % (11–35.6), 6% (0–14)
1 year; RIC: 22.5% (17.5–27), 18% (13–22) at 1 year]. We showed
a high percentage of long-term OS after HSCT for CLL either after
Std or RIC without any difference between the 2 groups except
for the AGVHD and an important impact of disease status
pretransplant; age, PS and sex-matching on the global OS.15
LANGERHANS CELL CHIMERISM AFTER MYELOABLATIVE VERSUS NON-
MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION
Kirkorian, Y.1, Collin, M.1, Leboeuf, M.1, Bogunovic, M.1, Wood, B.4,
Hackman, R.C.2,5, Storer, B.2,6, Storb, R.2,3, Merad, M.1,
Mielcarek, M.2,3 1Mount Sinai School of Medicine, New York, NY;
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5University of Washington, Seattle, WA; 6University of Washington,
Seattle, WA
Host antigen presenting cells have been shown to play an impor-
tant role in triggering graft-versus-host disease (GVHD) in animal
models of allogeneic hematopoietic cell transplantation (HCT).
To determine whether kinetics of skin LC-chimerism, as assesses
by combined XY-FISH and Langerin-immunohistochemistry
among recipients of sex-mismatched grafts, are influenced by condi-
tioning-intensity in human patients, we prospectively obtained skin
biopsies before and after myeloablative (MA) and nonmyeloablative
(NMA) HCT. The conversion-kinetics of LC-chimerism were then
compared to those of dendritic cells (DC) in peripheral blood (pB)
and bone marrow (BM), and CD3 T-cells and CD56 NK-cells in
pB. Of the 28 patients analyzed, 11 had received MA conditioning
(12 Gy total body irradiation [TBI] and cyclophosphamide, n 5 5;
treosulfan and fludarabine, n 5 4; busulfan and cyclophosphamide,
n 5 2) and 17 had received NMA conditioning (2 Gy TBI
alone, n 5 2; 2 Gy TBI and fludarabine, n 5 13; 3 Gy TBI and flu-
darabine, n 5 2). All patients were transplanted for hematologic
malignancies and were given PBSC (n 5 27) or BM grafts (n 5 1)
from HLA-matched related (n 5 12) or unrelated (n 5 16) donors.
The median degree of day-28 donor LC-chimerism among all pa-
tients was 13% (range, 0–100%), which corresponded to 91%
(range, 0–100%) and 8% (0–100%) for patients given MA and
NMA conditioning, respectively (p 5 0.0008).Level of donor Langerhans cell (LC), dendritic cell (DC), T-cell
andNK-cell chimerismon day-28 after transplant according to
conditioning-intensity and tissue-compartment
Conditioning IntensityMyeloablative (n511) Non-Myeloablative (n517)% Median donor chimerism (range)Skin-LC 91 (0-100) 8 (0-100)
pB-DC 100 (90-100) 100 (93-100)
BM-DC 100 (82-100) 100 (96-100)
pB-T-cell 99 (85-100) 78 (57-100)
pB-NK-cell Not determined 100 (55-100)pB, peripheral blood; BM, bone marrow.
Only 3 of the 17 patients (18%) with NMA conditioning had day-
28 donor LC-chimerism of .50%, which corresponded to 9 of 11
patients (82%) with MA conditioning. Two of the 3 NMA transplant
recipients with.50% LC-chimerism were the only patients given 3
Gy TBI instead of the standard 2 Gy TBI. The median degrees of
day-28 donor chimerism for the other cell populations examined
were as follows: pB-DC, 100% (range, 93–100%); BM-DC, 96%
(range, 96–100%); pB-T-cells, 78% (range, 57–100%); and pB-
NK-cells, 100% (55–100%). Skin LC-chimerism levels did not cor-
relate with those of blood cell populations. In conclusion, although
circulating DCs and lymphocytes were largely donor-derived by
day-28 after transplant regardless of conditioning-intensity, LCs re-
mained predominantly host-derived after NMA conditioning. Lon-
ger follow-up is needed to determine whether kinetics of DC/LC-
chimerism may predict GVHD-characteristics and GVT-effects,
information that could be used for individualizing immunosuppres-
sive therapy and thereby lowering the toxicity of allogeneic HCT.16
PRACTICE PATTERNS FOR EVALUATION, CONSENT AND CARE OF
RELATED DONORS AND RECIPIENTS AT HEMATOPOIETIC STEM CELL
TRANSPLANT CENTERS IN THE UNITED STATES: IS CONFLICT-OF-
INTEREST AN UNRECOGNIZED ISSUE?
O’Donnell, P.1, Pedersen, T.2, Confer, D.2, Pulsipher, M.3, Rizzo, J.D.4,
Stroncek, D.5, Leitman, S.5, Anderlini, P.6 1Fred Hutchinson Cancer Re-
search Center, Seattle, WA; 2Center for International Blood and Marrow
Transplant Research, Minneapolis, MN; 3University of Utah Medical
Center, Salt Lake City, UT; 4Medical College of Wisconsin, Milwaukee,
WI; 5National Institutes of Health, Bethesda, MD; 6MD Anderson
Cancer Center, Houston, TX
An argument can be made that a real or perceived conflict-of-
interest may arise in the situation where the same physician is
responsible for the care of two individuals whose care is interdepen-
dent. Care of donors and recipients in tissue transplantation may
represent an example. In hematopoietic stem cell transplantation
(HSCT) from unrelated donors facilitated by the National Marrow
Donor Program and in the setting of solid organ transplantation
from living donors, the standard-of-care is for donors and recipi-
ents to be under the care of separate physicians in order to provide
unbiased care and eliminate the potential for a conflict-of-interest.
However, the practice patterns of evaluation and care of related do-
nors and recipients at centers performing HSCT are unknown. Ac-
cordingly, a practice pattern survey of transplant centers in the
United States reporting to the CIBMTR was conducted by the Do-
nor Health and Safety Committee between December 2007 and
July 2008. The survey was administered as an online survey tool
sent to the center medical directors. The survey focused primarily
on determining the type of provider involved in medical clearance,
informed consent and medical management of the donor and the
relationship of that provider to the recipient. Of 258 centers sur-
veyed, 87 centers responded (33%). The median number of related
donor transplants per year at responding institutions was 16 (range:
1–115); the median total number of transplants per year was 70 (5–
450). As shown in the table, transplant physicians in no less than
70% of centers were involved in overlapping care of the donor
and the recipient during the donor evaluation, clearance and
Oral Presentations 9collection phases. These patterns were similar between transplant
teams caring for adult or pediatric donors and recipients. Among
responding centers, it appears that medical management of recipi-
ents and their related donors by the same provider is common, and
may not be viewed as a potential conflict-of-interest. Whether this




Clearance Consent ManagementProvider responsible for donor care
Internist/Family Practitioner 1 (1) 0 (.) 2 (2)
Pediatrician 5 (6) 1 (1) 3 (3)
Heme/Onc Physician 5 (6) 2 (2) 2 (2)
Transplant Physician 71 (82) 72 (83) 78 (90)
Mid-level Provider 3 (3) 7 (8) 2 (2)
Nurse 0 (.) 3 (3) 0 (.)
Missing 2 (2) 2 (2) 2 (2)Role of donor provider in
care of Recipient
Simultaneous responsibility
for recipient’s care25 (29) 31 (36) 35 (40)May be involved in recipient’s care 38 (44) 35 (40) 32 (37)
Not involved in recipient’s care 16 (18) 17 (20) 14 (16)
Not involved in transplant
program or recipient’s care6 (7) 2 (2) 4 (5)Missing 2 (2) 2 (2) 2 (2)*No. Responding Centers (%).17
BK VIRUS INFECTION IS ASSOCIATED WITH HEMATURIA AND RENAL
IMPAIRMENT IN RECIPIENTS OF ALLOGENEIC HEMATOPOETIC STEM
CELL TRANSPLANTS
O’Donnell, P.H.1, Swanson, K.1, Josephson,M.A.2, Artz, A.S.1, Rich, E.1,
Stock,W.1, van Besien, K.1 1The University of Chicago, Chicago, IL; 2The
University of Chicago, Chicago, IL
BK virus (BKV) is an important pathogen and cause of nephrop-
athy in recipients of renal transplants, but its clinical significance in
patients (pts) following hematopoetic stem cell transplantation
(HSCT) is less well described. Over a 16 month period we prospec-
tively measured BKV in the blood and urine of 124 pts who had
undergone allogeneic HSCT [HLA-identical donor (n 5 70), alter-
native-donor (HLA-mismatched-related, matched-unrelated, or
cord) (n 5 54)] between 1998–2007 and who were receiving
in- or outpatient post-transplant care. Most pts (73%) received
alemtuzumab-containing regimens. BK viruria was manifest at
some time in 64.8% of pts; 16.9% developed BK viremia. All pts
with BK viremia also had viruria. BK viruria developed at a median
time post-HSCT of 24 d (range 3–138 d), while viremia was de-
tected at a significantly longer median time of 128 d (range 62–
307 d) (P\0.0001). Among clinical factors (disease, transplant
type, alemtuzumab use, CMV viremia, GVHD, HLA C locus sta-
tus), only CMV viremia was significantly more common in pts with
BK viruria and viremia. Given the association of BKV with hemor-
rhagic cystitis, urinalyses from all pts were analyzed for the pres-
ence and number of red blood cells. There was a direct
relationship between higher median and maximum levels of urinary
BKV with both an increased occurrence, and greater degree, of mi-
croscopic hematuria (P\0.03). BK viremia was also associated with
the development of hematuria (P 5 0.03). Finally, BKV infection
was analyzed along with other clinical factors in relation to the de-
velopment of post-HSCT renal impairment. On multivariate anal-
ysis, only BK viremia (P 5 0.000001) and undergoing an
alternative-donor transplant (P 5 0.002) were independent predic-
tors of development of post-HSCT renal impairment, with BK
viremia associated with a median 1.62 mg/dL rise in creatinine
from the pre-transplant baseline. Two pts with BK viremia
developed biopsy-proven BKV nephropathy, with both requiring
hemodialysis. In summary, BK viruria is a common early findingin pts undergoing allogeneic HSCT, and higher urinary BKV levels
are directly related to increased hematuria. BK viremia occurs later
and less commonly, is associated with hematuria, and is an inde-
pendent predictor of worsening renal function post-HSCT. Inves-
tigation of whether prophylaxis against, or treatment of, BKV in the
post-HSCT setting mitigates the associated morbidities, especially
kidney injury, warrants prospective evaluation.18
HHV6 REACTIVATION IS AN IMPORTANT RISKFACTOR FOR POOR
OUTCOMES IN MYELOABLATIVE, BUT NOT IN NON-MYELOABLATIVE
TREATED ALLOGENEIC HSCT PATIENTS
Pagter, A.P.J.1, Meijer, E.4, Keukens, L.1, Schutten, M.5,
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Background: Haematopoietic stem cell transplantation (HSCT)
is complicated by viral reactivations. Viral reactivations are major
complications after HSCT. The role of Human Herpesvirus type
6 (HHV6) in complications after HSCT remains unclear. We found
a strong association between HHV6 reactivation and poor outcome
after HSCT in children after myeloablative conditioning regimens.
Risk factors for the development of HHV6 reactivation in adults
are unknown. We investigated the association of HHV6 reactivation
and clinical outcomes.
Methods: In a retrospective cohort study (January 2005- Decem-
ber 2007), HHV6 DNA loads in plasma were monitored by realtime
PCR in adult patients after allogeneic HSCT in two HSCT-centers
in the Netherlands (Utrecht and Rotterdam). Previously, Epstein
Barr virus (EBV)- and cytomegalovirus (CMV) DNA loads were
prospectively monitored in these patients. EBV- and CMV-reactiva-
tions were pre-emptive treated according to local guidelines. HHV6
reactivation was defined as viral DNA load $1000 cp/mL. Associa-
tions between outcomes and various variables (age, gender, HSCT
center, donor source, HLA match of donor and recipient, myeloa-
blative (MA) versus non-myeloablative (NMA) conditioning regi-
men, EBV- and CMV-reactivation) were analyzed using Cox
proportional hazard models.
Results: 108 patients (60 MA and 48 NMA recipients; 49
Utrecht and 59 Rotterdam) between 2005 and 2007 were in-
cluded (median age 40.1; range 18- 66 years). Median follow-
up was 20 (range 1.4–35.8) months. 16/60 (27%) MA patients
had HHV6 reactivation (mean 50323 cp/mL) compared to 2/
48 (4%) NMA patients with marginal HHV6 reactivation
(mean 1000 cp/mL). Median time of reactivation for HHV6 in
MA patients was 19 (range 10–35) days, compared to 14 and
35 days in the 2 NMA patients. In multivariate analysis, MA con-
ditioning was the only predictor for HHV6 reactivation (HR
0.15; 95%CI 0.03–0.65; p 5 0.012). In addition, HHV6 reactiva-
tion was the only predictor for grade $2 acute Graft versus
host disease (HR 6,2, 95%CI 2,8- 13,9; p 5 0.000) and
Transplantation related mortality (HR 3,9, 95% CI 1.4–10.7;
p 5 0.010).
Conclusions: Early HHV6 reactivation is more common after
MA than after NMA conditioning treatment and is associated with
poor survival and severe acute GvHD. Screening for HHV6 reacti-
vation might be important in the MA treated patients since early ini-
tiation of pre-emptive or prophylactic anti-viral treatment might
influence the outcomes.19
NATURAL KILLER (NK) CELLS ARE RESISTANT TO THE APOPTOTIC EF-
FECTS OF CORTICOSTEROIDS COMPARED TO T CELLS: IMPLICATIONS
FOR ADOPTIVE NK CELL THERAPY FOLLOWING ALLOGENEIC HCT
Ramanathan, M., Lundqvist, A., Yokoyama, H., Smith, A., Childs, R.
National Institute of Health, Bethesda, MD
In vivo animal data and preliminary data in humans show donor
NK cells can mediate antitumor effects against malignancies when
adoptively infused following allogeneic hematopoietic cell
